Centessa Pharmaceuticals PLC ADR (CNTA) Stock
CNTA is no longer traded. Centessa Pharmaceuticals PLC ADR was acquired by Eli Lilly (LLY) in June 2026.
Each CNTA share was exchanged for $38.00 in cash upfront plus a contingent value right. Prices on this page are historical; the last trade was June 23, 2026 at $40.50.
See Eli Lilly (LLY) stock →Centessa Pharmaceuticals PLC ADR stock price history
CNTA final trading statistics
- Final close
- $40.50
- Final trading day
- Jun 23, 2026
- Market cap at delisting
- $6.27B
- Shares outstanding
- 154.73M
- Final 52-week range
- $12.74 – $40.56
- Avg. volume (final 3 mo.)
- 2,932,410
- All-time high (split-adj.)
- $40.50 · Jun 2026
- All-time low (split-adj.)
- $3.03 · Feb 2023
- Return since IPO
- +86.2%
- Beta
- 1.12
- Book value / share
- $3.15
- Price / book
- 12.86
Centessa Pharmaceuticals PLC ADR annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2025 | $15.00M | -$197.5M | -$1.47 |
| FY2024 | $0.00 | -$235.8M | -$1.99 |
| FY2023 | $6.85M | -$151.1M | -$1.57 |
| FY2022 | $0.00 | -$216.2M | -$2.31 |
| FY2021 | — | -$381.9M | -$1.90 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Centessa Pharmaceuticals PLC ADR
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Centessa Pharmaceuticals PLC ADR stock FAQ
What happened to Centessa Pharmaceuticals PLC ADR stock?
Centessa Pharmaceuticals PLC ADR was acquired by Eli Lilly (LLY) in June 2026. Shareholders received $38.00 in cash upfront plus a contingent value right for each share. CNTA stock stopped trading on the Nasdaq, with a final close of $40.50 on June 23, 2026.
What did Centessa Pharmaceuticals PLC ADR shareholders receive?
Each CNTA share was converted into $38.00 in cash upfront plus a contingent value right. The deal was valued at about $7.8 billion.
Is CNTA stock still trading?
No. CNTA was delisted from the Nasdaq in June 2026 and no longer trades on a U.S. exchange.
What was the last price of CNTA stock?
CNTA closed at $40.50 on its final trading day, June 23, 2026, for a market value of about $6.27B.
What were Centessa Pharmaceuticals PLC ADR's revenue and earnings in its last full fiscal year?
Centessa Pharmaceuticals PLC ADR reported revenue of $15.00M and net income of -$197.5M in fiscal 2025, its last full year as a public company.
When did Centessa Pharmaceuticals PLC ADR go public?
Centessa Pharmaceuticals PLC ADR stock began trading on May 28, 2021.